Drug Profile
Research programme: eye disorder therapies - Formosa Pharmaceuticals/Nxera Pharma
Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Activus Pharma; Sosei Heptares
- Developer Activus Pharma; Formosa Pharmaceuticals; Nxera Pharma
- Class Anti-inflammatories; Eye disorder therapies; Fluorinated steroids; Glucocorticoids
- Mechanism of Action Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders; Ocular inflammation
- Discontinued Infectious conjunctivitis